Our lead compound is axelopran, a peripherally restricted MOR antagonist, with potent immune infiltration into cancer. Axelopran has successfully completed Phase 1 safety studies with no major immune-related adverse events and has over 500 patients in its safety database.

Our pre-clinical program met our major milestone on demonstrating efficacy in multiple solid tumor types and includes studies of efficacy in combination with immune checkpoint inhibitors, anti-PD1.